iBody
Rapid Monoclonal Antibody Discovery
Product Basics
Rapid Rabbit & Human Monoclonal Antibody Discovery — Sequences Identified in as Little as One Month
iBody provides a comprehensive, collaborative antibody discovery service using its patented “Ecobody” technology and works closely with customers to efficiently identify high-quality monoclonal antibody sequences, often in as little as one month.
Key Features
- Generates hard-to-make monoclonal antibodies
Produces rabbit monoclonal antibodies that bind small molecules, detect subtle amino acid differences, and recognize post-translational modifications.
- Delivers high-affinity, high-specificity rabbit antibodies
Leverages rabbit antibody diversity and longer CDRs to achieve superior binding performance compared with mouse antibodies.
- Enables rapid antibody screening with Ecobody technology
Uses a cell-free system to evaluate antibodies quickly and exhaustively while preserving antibody diversity.
- Offers end-to-end custom antibody services
Provides tailored support from antigen preparation and rabbit immunization to antibody discovery and recombinant antibody production.
Technical Information
What is “Ecobody” Technology?
“Ecobody” is a patented technology developed at Nagoya University, Japan, which enables to obtain and evaluate useful antibodies produced in humans and animals exhaustively and rapidly.
Benefits of “Ecobody” Technology
Ecobody technology combines a single-cell method with cell-free in vitro expression to enable rapid, exhaustive monoclonal antibody discovery. By isolating antibody genes directly from individual human and animal B cells using single-cell RT-PCR, iBody preserves the original antibody diversity without requiring B cell immortalization or proliferation, reducing the risk of cell loss. Fab antibodies are then expressed in a homogeneous cell-free system and evaluated by ELISA, allowing fast, reliable screening and antibody evaluation in as little as two days.
Comparison with other methods
Learn more about the “Ecobody” technology
The main steps in the monoclonal antibody generating service using “Ecobody” technology are as follows
Deliverables
Antibody gene and sequence information (10 clones) Recombinant antibodies
Case Studies
- Developed antibodies for a pancreatic cancer marker with high sensitivity and broad application
- Developed a highly sensitive antibody for phosphorylated peptide
- Obtained human monoclonal antibodies with neutralizing activity against diverse SARS-CoV-2 variants
Pricing
Please feel free to contact us for consultations or quotes for the specificity and usage of your desired antibody. We will propose a plan for antibody production, including antigen design, antibody selection methods based on the antigen type and application, and antibody format and tag selection.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Reference & Literature
- Ojima-Kato, T. et al. Rapid Generation of Monoclonal Antibodies from Single B Cells by Ecobody Technology. Antibodies 7, 38 (2018) doi: 10.3390/antib7040038.
- Ojima-Kato, T., Nagai, S. & Nakano, H. Ecobody technology: rapid monoclonal antibody screening method from single B cells using cell-free protein synthesis for antigen-binding fragment formation. Scientific Reports 7, 13979 (2017) doi: 10.1038/s41598-017-14277-0.
- Ojima-Kato, T., Nagai, S. & Nakano, H. N-terminal SKIK peptide tag markedly improves expression of difficult-to-express proteins in Escherichia coli and Saccharomyces cerevisiae. Journal of Bioscience and Bioengineering 123, 540–546 (2017) doi: 10.1016/j.jbiosc.2016.12.004.
- Ojima-Kato, T. et al. ‘Zipbody’ leucine zipper-fused Fab in E. coli in vitro and in vivo expression systems. Protein Engineering, Design and Selection 29, 149–157 (2016) doi: 10.1093/protein/gzw001.
Related Products
FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES